Quality/GMPs

Latest News


Digitalization of QbD Risk Assessments

The digital transformation of quality-by-design assessment workflows can improve efficiency, reduce human errors, and facilitate integration within a much broader digital ecosystem.

Digitalization of QbD Risk Assessments

Subjectivity in Quality Risk Management

The authors discuss subjectivity in the ICH Q9 (R1) guidance document.

Subjectivity in Quality Risk Management

Phase-appropriate Compliance for Cell and Gene Therapies

Understanding how to apply phase-appropriate GMPs is crucial for achieving successful regulatory approval.

Phase-appropriate Compliance for Cell and Gene Therapies

Data supporting the quality and safety of product must meet the ALCOA+ elements in order to avoid regulatory citations for data integrity issues, says Susan J. Schniepp, executive vice-president of post-approval pharma and distinguished fellow, Regulatory Compliance Associates.

Software systems can help validate pharmaceutical manufacturing and steer the most appropriate design of processes in the right direction.